{
  "abstract": "Acromegaly management in the Gulf region is complicated by a high burden of metabolic comorbidity, frequent presentation with macroadenomas and suboptimal biochemical control in available regional cohorts. Conventional first-generation somatostatin receptor ligands achieve biochemical control in only 30-40% of patients, rates lower than those observed in European cohorts, necessitating precision medicine strategies. MRI signal and tumour granulation patterns represent the most widely available biomarkers in Gulf healthcare systems and enable precise treatment selection. These biomarkers may help predict poor first-generation therapy response while identifying patients who may benefit from pasireotide, an efficacious second-generation somatostatin receptor ligand with multi-receptor binding capacity. Implementation of biomarker-guided therapy in Gulf healthcare systems can optimize therapeutic outcomes while addressing regional challenges of delayed diagnosis and advanced disease presentation. Regional challenges specific to Gulf healthcare systems are identified and a practical biomarker-guided algorithm tailored for the GCC region is proposed to optimise treatment selection using readily available diagnostic tools. This approach is more appropriate for Gulf populations who present with more advanced disease characteristics that may benefit from precision-guided first-line treatment selection, representing a paradigm shift away from current guideline recommendations toward truly personalised medicine. This evolution from empirical to precision medicine represents a potential advancement for improving acromegaly management where complex metabolic phenotypes demand sophisticated treatment strategies.",
  "abstract_shown": true,
  "affiliations": [
    "Qatar Metabolic Institute, Department of Medicine, Hamad Medical Corporation",
    "Division of Endocrinology, Tawam Hospital & Sheikh Tahnoon Bin Mohammed Medical City (STMC)",
    "Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University",
    "Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Second Health Cluster",
    "College of Medicine, Alfaisal University",
    "Endocrinology & Diabetes Unit, Department of Medicine, College of Medicine and King Saud University Medical City, King Saud University",
    "Department of Medicine, King Faisal Specialist Hospital and Research Center",
    "Molecular Endocrine Section, Research and Innovation, King Faisal Specialist Hospital and Research Center"
  ],
  "article_type": "brief report",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Tarik Elhadd"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Khaled Aldahmani"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Mussa Almalki"
    },
    {
      "affs": [
        5
      ],
      "name": "Aisha Ekhzaimy"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Raya Almazrouei"
    },
    {
      "affs": [
        0
      ],
      "name": "Zainab Dabbous"
    },
    {
      "affs": [
        0
      ],
      "name": "Zaina Rohani"
    },
    {
      "affs": [
        6,
        7
      ],
      "name": "Ali Alzahrani"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4c0js95z1cjtd.bib",
  "cited_by": 0,
  "doi": "10.3389/fendo.2026.1951420",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13710002/",
  "id": "4c0js95z1cjtd",
  "issns": [
    "1664-2392"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fendo.2026.1951420/full",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Perspective"
    ],
    [
      "openalex",
      "2712|Pituitary Gland Disorders and Treatments"
    ]
  ],
  "openalex": "W7221665719",
  "pdf_url": "https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1951420/pdf",
  "pmcid": "PMC13710002",
  "pmid": "42947680",
  "published": "2026-10-13",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/4c0js95z1cjtd.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:20Z",
      "native_id": "10.3389/fendo.2026.1951420",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fendo.2026.1951420/full"
    },
    {
      "first_seen": "2026-10-31T12:21:03Z",
      "native_id": "PMC13710002",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fendo.2026.1951420"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2712|Pituitary Gland Disorders and Treatments",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Personalised acromegaly treatment: implementing precision medicine in the Gulf States",
  "title_text": "Personalised acromegaly treatment: implementing precision medicine in the Gulf States",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:21:03Z",
  "url": "https://research.draconitic.com/paper/4c0js95z1cjtd",
  "venue": "Frontiers in Endocrinology",
  "versions": []
}